# Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children

> **NCT00163618** · — · COMPLETED · sponsor: **Pfizer**

## Conditions studied

- Encephalitis, Tick-borne

## Interventions

- **BIOLOGICAL:** Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl

## Key facts

- **NCT ID:** NCT00163618
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** —
- **Final completion:** 2006-07
- **Target enrollment:** — (—)
- **Last updated:** 2015-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00163618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00163618, "Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00163618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*